TYBR Health
Summary active Updated Jul 22, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Founders
About
TYBR Health is a Houston-based regenerative medicine and medical device company focused on improving post-surgical soft-tissue healing 12. The company’s flagship product, the B3 GEL System, is an FDA-cleared flowable extracellular matrix hydrogel designed to protect tendons, ligaments, muscles, and surrounding tissues during recovery from orthopedic procedures 12. The B3 GEL System received FDA clearance in June 2025 and launched commercially in the U.S. in January 2026 2.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-07-21 | Series A | $30M | Vensana Capital, Mutual Capital Partners | Neovate Capital Partners 12 |
Proceeds will expand commercial access to the B3 GEL System, broaden clinical indications, and fund clinical studies of the product’s protective role during orthopedic surgery 12.
What Investors Say
Greg Banker, Vensana Capital: “B3 GEL adheres where applied, conforms to anatomy, and forms a protective barrier through healing” 1.
Liz Todia Zambory, Mutual Capital Partners: “TYBR addresses a gap surgeons have long lived with, fitting existing workflows” 1.
What Founders Say
Tim Keane, Co-Founder and CEO: “Managing the healing environment should complement good surgical technique and contribute to better recovery for patients” 2.
Sources
-
PR Newswire, “TYBR Health Announces $30 Million Series A Financing to Expand Access to the B3 GEL System,” July 21, 2026. Accessed July 22, 2026. https://www.prnewswire.com/news-releases/tybr-health-announces-30-million-series-a-financing-to-expand-access-to-the-b3-gel-system-302830733.html↩↩↩↩↩↩
-
Medical Device Network, “TYBR Health lands $30m to advance orthopaedic hydrogel platform,” July 22, 2026. Accessed July 22, 2026. https://www.medicaldevice-network.com/news/tybr-health-lands-30m-to-advance-orthopaedic-hydrogel-platform/↩↩↩↩↩↩